ZA200105543B - Improved saponin adjuvant compositions and methods relating thereto. - Google Patents
Improved saponin adjuvant compositions and methods relating thereto. Download PDFInfo
- Publication number
- ZA200105543B ZA200105543B ZA200105543A ZA200105543A ZA200105543B ZA 200105543 B ZA200105543 B ZA 200105543B ZA 200105543 A ZA200105543 A ZA 200105543A ZA 200105543 A ZA200105543 A ZA 200105543A ZA 200105543 B ZA200105543 B ZA 200105543B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition according
- dextran
- adjuvant
- composition
- ionic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 239000002671 adjuvant Substances 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims abstract description 10
- 229930182490 saponin Natural products 0.000 title claims description 21
- 150000007949 saponins Chemical class 0.000 title claims description 20
- 239000001397 quillaja saponaria molina bark Substances 0.000 title claims description 18
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 34
- 230000002163 immunogen Effects 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 229920002307 Dextran Polymers 0.000 claims abstract description 21
- 150000004676 glycans Chemical class 0.000 claims abstract description 17
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 17
- 239000005017 polysaccharide Substances 0.000 claims abstract description 17
- 230000028993 immune response Effects 0.000 claims abstract description 16
- 229960003983 diphtheria toxoid Drugs 0.000 claims abstract description 10
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims description 15
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims description 15
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims description 15
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 6
- 229920002521 macromolecule Polymers 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 abstract description 8
- 230000001850 reproductive effect Effects 0.000 abstract description 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 16
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000011161 development Methods 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000000240 adjuvant effect Effects 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001092142 Molina Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- -1 Quil A saponins Chemical class 0.000 description 1
- 241001454523 Quillaja saponaria Species 0.000 description 1
- 235000009001 Quillaja saponaria Nutrition 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000000601 hypothalamic hormone Substances 0.000 description 1
- 229940043650 hypothalamic hormone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001592 luteinising effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007758 mating behavior Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 125000003523 triterpene group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPP8073A AUPP807399A0 (en) | 1999-01-08 | 1999-01-08 | Improved immunogenic lhrh composition and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200105543B true ZA200105543B (en) | 2003-01-22 |
Family
ID=3812278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200105543A ZA200105543B (en) | 1999-01-08 | 2001-07-05 | Improved saponin adjuvant compositions and methods relating thereto. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9579379B1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1140165B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4949555B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE410183T1 (cg-RX-API-DMAC7.html) |
| AU (2) | AUPP807399A0 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2660344A1 (cg-RX-API-DMAC7.html) |
| CY (1) | CY1108693T1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69939706D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1140165T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2317708T3 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ512011A (cg-RX-API-DMAC7.html) |
| PT (1) | PT1140165E (cg-RX-API-DMAC7.html) |
| TW (1) | TW533079B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000041720A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200105543B (cg-RX-API-DMAC7.html) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU783344B2 (en) | 1999-02-17 | 2005-10-20 | Csl Limited | Immunogenic complexes and methods relating thereto |
| GB0008879D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
| GB0008877D0 (en) * | 2000-04-12 | 2000-05-31 | Astrazeneca Ab | Polypeptide delivery system |
| WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
| AU2005335104C1 (en) * | 2004-07-18 | 2010-10-28 | Csl Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| CA2609244A1 (en) * | 2005-06-01 | 2006-12-07 | Pfizer Products Inc. | Vaccine compositions and methods for the treatment of urinary incontinence |
| WO2008110912A1 (en) * | 2007-03-14 | 2008-09-18 | Pfizer Inc. | Fertility regulation in horses |
| SG10201400388QA (en) | 2008-12-09 | 2014-05-29 | Pfizer Vaccines Llc | IgE CH3 peptide vaccine |
| EP2424562B1 (en) | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
| MX2012001194A (es) | 2009-07-30 | 2012-03-07 | Pfizer Vaccines Llc | Peptidos tau antigenicos y usos de los mismos. |
| NZ620441A (en) | 2009-09-03 | 2015-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
| SG10201408505SA (en) | 2009-12-22 | 2015-02-27 | Celldex Therapeutics Inc | Vaccine compositions |
| WO2011154863A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
| CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
| US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
| ES2963147T3 (es) * | 2011-05-13 | 2024-03-25 | Zoetis Services Llc | Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah |
| JP6281163B2 (ja) | 2011-08-22 | 2018-02-21 | エメルゲント バイオソリューションズ カナダ | クロストリジウム・ディフィシレ抗体 |
| EP2659907A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| RU2666141C2 (ru) | 2013-09-17 | 2018-09-06 | Оби Фарма, Инк. | Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака |
| CA3060664A1 (en) | 2013-09-19 | 2015-03-26 | Zoetis Services Llc | Water-in-oil emulsions comprising immunostimulatory oligonucleotides |
| KR20160077214A (ko) | 2013-12-16 | 2016-07-01 | 조에티스 서비시즈 엘엘씨 | 헨드라 및 니파 바이러스 ｇ 당단백질 면역원성 조성물 |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PT3096785T (pt) | 2014-01-21 | 2020-10-13 | Pfizer | Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| KR20170041167A (ko) | 2014-02-19 | 2017-04-14 | 조디 베리 | 마르부르크 단클론성 항체 |
| JP2017512759A (ja) | 2014-04-10 | 2017-05-25 | オービーアイ ファーマ インコーポレイテッド | 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途 |
| MX395525B (es) | 2015-01-15 | 2025-03-25 | Pfizer | Composiciones inmunogenicas para usar en vacunas neumococicas. |
| LT3244920T (lt) * | 2015-01-16 | 2023-08-25 | Zoetis Services Llc | Snukio ir nagų ligos vakcina |
| CA2986494A1 (en) | 2015-06-03 | 2016-12-08 | Affiris Ag | Il-23-p19 vaccines |
| AU2016289497A1 (en) | 2015-07-07 | 2017-12-07 | Affiris Ag | Vaccines for the treatment and prevention of IgE mediated diseases |
| AU2016295566B2 (en) | 2015-07-21 | 2019-06-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| US10935544B2 (en) | 2015-09-04 | 2021-03-02 | Obi Pharma, Inc. | Glycan arrays and method of use |
| SI3307322T1 (sl) | 2015-09-04 | 2021-08-31 | Primatope Therapeutics Inc. | Humanizirana protitelesa proti CD40 in njihove uporabe |
| EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US11041017B2 (en) | 2016-03-29 | 2021-06-22 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017185089A2 (en) | 2016-04-22 | 2017-10-26 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| WO2018022933A1 (en) | 2016-07-27 | 2018-02-01 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ，インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
| WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| US11413344B2 (en) | 2017-01-20 | 2022-08-16 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US11547672B2 (en) | 2018-09-14 | 2023-01-10 | Massachusetts Institute Of Technology | Nanoparticle vaccine adjuvant and methods of use thereof |
| US20220016229A1 (en) | 2018-12-12 | 2022-01-20 | Pfizer Inc. | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof |
| US11419932B2 (en) | 2019-01-24 | 2022-08-23 | Massachusetts Institute Of Technology | Nucleic acid nanostructure platform for antigen presentation and vaccine formulations formed therefrom |
| CN109663126A (zh) * | 2019-03-01 | 2019-04-23 | 龙阔（苏州）生物工程有限公司 | 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| CN112516325B (zh) * | 2019-09-18 | 2023-12-08 | 洛阳赛威生物科技有限公司 | 一种稳定的口蹄疫疫苗组合物及其应用 |
| KR20220092572A (ko) | 2019-11-01 | 2022-07-01 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그 방법 |
| MX2022010350A (es) | 2020-02-23 | 2022-09-19 | Pfizer | Composiciones de esquerichia coli y sus metodos. |
| CN113967252B (zh) * | 2020-07-24 | 2024-03-26 | 洛阳赛威生物科技有限公司 | 一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| AU2021368151B2 (en) | 2020-10-27 | 2024-09-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2022097010A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
| WO2023114570A1 (en) | 2021-12-19 | 2023-06-22 | Massachusetts Institute Of Technology | Compositions and methods for long-lasting germinal center responses to a priming immunization |
| CA3243932A1 (en) | 2022-02-14 | 2023-08-17 | University Of Georgia Research Foundation, Inc. | PAN-PNEUMOVIRUS VACCINE COMPOSITIONS AND THEIR METHODS OF USE |
| WO2025010482A1 (pt) * | 2023-07-07 | 2025-01-16 | Ouro Fino Saúde Animal Ltda | Peptídeo de gnrh modificado e seu conjugado para imunocastração de mamíferos, método de fabricação, composição e kit |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1924304C3 (de) * | 1969-05-13 | 1980-07-17 | Bayer Ag, 5090 Leverkusen | Diäthylaminoäthyldextran (DEAE-D) als Adjuvans für Impfstoffe zur aktiven Immunisierung von Säugetieren |
| DE3411224A1 (de) | 1984-03-27 | 1985-10-10 | Hoechst Ag, 6230 Frankfurt | Verfahren zur racematarmen herstellung von peptidzwischenprodukten der gonadorelin- und gonadorelinanaloga-synthese und neue zwischenprodukte bei diesem verfahren |
| DK166762B1 (da) * | 1986-01-14 | 1993-07-12 | Nederlanden Staat | Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser |
| NZ221306A (en) | 1986-08-15 | 1990-02-26 | Commw Scient Ind Res Org | 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof |
| WO1988005308A1 (en) | 1987-01-14 | 1988-07-28 | Commonwealth Scientific And Industrial Research Or | Anti reproductive hormone |
| GB8707398D0 (en) * | 1987-03-27 | 1987-04-29 | Coopers Animal Health | Biologically active molecules |
| US4892830A (en) * | 1987-04-02 | 1990-01-09 | Baylor College Of Medicine | Environmentally controlled in vitro incubator |
| GB2228262B (en) | 1989-01-25 | 1992-10-07 | Nat Inst Immunology | Antigenic derivative of gnrh |
| WO1990009799A1 (en) | 1989-02-23 | 1990-09-07 | Colorado State University Research Foundation | GnRH ANALOGS FOR DESTROYING GONADOTROPHS |
| DE69027983T2 (de) * | 1989-08-25 | 1997-03-20 | Biotech Australia Pty Ltd | Fusionsproteine bestehend aus TraTp und mindestens einem LHRH-Analog |
| GB8919819D0 (en) * | 1989-09-01 | 1989-10-18 | Coopers Animal Health | Complexes having adjuvant activity |
| US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| GB8921470D0 (en) * | 1989-09-22 | 1989-11-08 | Peptide Technology Ltd | Vaccines |
| US5324512A (en) | 1990-12-26 | 1994-06-28 | The Population Council | [Gln']-luteinizing hormone releasing hormone conjugate of tetanus vaccine and its uses |
| US5837268A (en) | 1991-10-16 | 1998-11-17 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
| ZA934199B (en) | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
| US5650398A (en) * | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
| US5614487A (en) | 1993-05-28 | 1997-03-25 | Genentech, Inc. | Sustained release pharmaceutical composition |
| US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| AU7468196A (en) | 1995-10-27 | 1997-05-15 | Merck & Co., Inc. | Conjugates of gonadotropin releasing hormone |
| AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| AUPO776897A0 (en) * | 1997-07-09 | 1997-07-31 | Csl Limited | A method of achieving production gains in livestock and agents useful for same |
| US6013770A (en) | 1997-07-21 | 2000-01-11 | Washington State University | Chimeric contraceptive vaccines |
| AUPP060097A0 (en) * | 1997-11-28 | 1998-01-08 | Commonwealth Scientific And Industrial Research Organisation | Adjuvant system for enhanced response |
-
1999
- 1999-01-08 AU AUPP8073A patent/AUPP807399A0/en not_active Abandoned
- 1999-12-24 PT PT99968288T patent/PT1140165E/pt unknown
- 1999-12-24 US US09/857,797 patent/US9579379B1/en not_active Expired - Fee Related
- 1999-12-24 AU AU25263/00A patent/AU758133B2/en not_active Expired
- 1999-12-24 DK DK99968288T patent/DK1140165T3/da active
- 1999-12-24 NZ NZ512011A patent/NZ512011A/xx not_active IP Right Cessation
- 1999-12-24 JP JP2000593330A patent/JP4949555B2/ja not_active Expired - Lifetime
- 1999-12-24 CA CA002660344A patent/CA2660344A1/en not_active Abandoned
- 1999-12-24 DE DE69939706T patent/DE69939706D1/de not_active Expired - Lifetime
- 1999-12-24 CA CA2359111A patent/CA2359111C/en not_active Expired - Lifetime
- 1999-12-24 WO PCT/AU1999/001167 patent/WO2000041720A1/en not_active Ceased
- 1999-12-24 EP EP99968288A patent/EP1140165B1/en not_active Expired - Lifetime
- 1999-12-24 EP EP08005701A patent/EP1946773A3/en not_active Withdrawn
- 1999-12-24 ES ES99968288T patent/ES2317708T3/es not_active Expired - Lifetime
- 1999-12-24 AT AT99968288T patent/ATE410183T1/de active
- 1999-12-27 TW TW088123010A patent/TW533079B/zh not_active IP Right Cessation
-
2001
- 2001-07-05 ZA ZA200105543A patent/ZA200105543B/en unknown
-
2009
- 2009-01-07 CY CY20091100002T patent/CY1108693T1/el unknown
-
2011
- 2011-11-04 JP JP2011242133A patent/JP2012072157A/ja active Pending
-
2012
- 2012-03-14 US US13/420,082 patent/US9149520B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1140165B1 (en) | 2008-10-08 |
| ATE410183T1 (de) | 2008-10-15 |
| EP1140165A4 (en) | 2005-01-05 |
| EP1946773A2 (en) | 2008-07-23 |
| WO2000041720A8 (en) | 2000-11-09 |
| WO2000041720A1 (en) | 2000-07-20 |
| CA2660344A1 (en) | 2000-07-20 |
| CY1108693T1 (el) | 2012-05-23 |
| AU758133B2 (en) | 2003-03-13 |
| TW533079B (en) | 2003-05-21 |
| JP4949555B2 (ja) | 2012-06-13 |
| US9579379B1 (en) | 2017-02-28 |
| CA2359111A1 (en) | 2000-07-20 |
| US20120251566A1 (en) | 2012-10-04 |
| ES2317708T3 (es) | 2009-04-16 |
| CA2359111C (en) | 2014-02-18 |
| US9149520B2 (en) | 2015-10-06 |
| NZ512011A (en) | 2002-12-20 |
| DE69939706D1 (de) | 2008-11-20 |
| JP2002534480A (ja) | 2002-10-15 |
| AUPP807399A0 (en) | 1999-02-04 |
| PT1140165E (pt) | 2009-01-13 |
| JP2012072157A (ja) | 2012-04-12 |
| EP1140165A1 (en) | 2001-10-10 |
| AU2526300A (en) | 2000-08-01 |
| DK1140165T3 (da) | 2009-02-16 |
| EP1946773A3 (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200105543B (en) | Improved saponin adjuvant compositions and methods relating thereto. | |
| US8741303B2 (en) | Immunogenic LHRH compositions and methods relating thereto | |
| EP0464124B1 (en) | A peptide, immunogenic composition and vaccine or medicinal preparation; a method of immunising a mammal against lhrh, and a method of improving the meat quality of pigs | |
| US20040213817A1 (en) | Vaccine compositions and adjuvant | |
| US20050239701A1 (en) | Transient and/or permanent modification of sexual behavior and/or fertility using recombinant chimeric GnRH | |
| WO2008110912A1 (en) | Fertility regulation in horses | |
| WO2001034192A2 (en) | Improved method of immunization | |
| AU2006253914A1 (en) | Vaccine compositions and methods for the treatment of urinary incontinence |